Typically, large-scale capital increases are viewed negatively by investors due to concerns over dilution of existing shareholders' equity. However, Riga Chem Bio has bucked this trend. Following the announcement of a 500 billion won capital raise, the company's stock has surged, drawing significant market attention. Analysts attribute this positive response to the involvement of government policy funds, the largest shareholder, and institutional investors, indicating that this is not just a simple fundraising effort but a recognition of the company's global drug development competitiveness.
As of 1:46 PM on June 29, the Korea Exchange reported that Riga Chem Bio's stock rose by 20,600 won (14.42%) to 163,500 won. The stock showed strong gains from the market open and reached as high as 173,800 won during the morning session.
The catalyst for this increase was the announcement made on June 26 regarding the 500 billion won investment. Riga Chem Bio plans to raise this amount by issuing 330 billion won in third-party allocated convertible preferred shares (CPS) and 170 billion won in convertible bonds (CB). The funds will be allocated to late-stage clinical trials for antibody-drug conjugates (ADC) and the development of new pipelines.
The key aspect of this investment is not just the amount but the investors involved. The Financial Services Commission has decided that the Advanced Strategic Industry Fund will invest 250 billion won, half of the total amount, through the National Growth Fund's fund management committee. The remaining 250 billion won will come from the largest shareholder, Fan Orion, and domestic institutional investors.
Market analysts view this as a case where both the government and private sector have validated future growth potential. Unlike typical capital increases in biotech firms, which often focus on securing operational funds, Riga Chem Bio is seen as a company that has already proven its global technological capabilities and is now seeking growth investments to accelerate late-stage clinical trials and commercialization.
Notably, the investment is characterized as 'patient capital' with a duration of up to 10 years. Given that drug development requires substantial funding and takes years to yield results, securing long-term capital is crucial for a company's competitiveness. This investment allows Riga Chem Bio to pursue global clinical trials and next-generation platform development without short-term financial pressure.
The government's direct investment reflects its high regard for the growth potential of the ADC industry. ADCs represent a next-generation cancer treatment platform that combines antibodies targeting cancer cells with potent anti-cancer agents, minimizing damage to healthy cells while enhancing therapeutic efficacy. This area has become one of the most competitive fields for investment among global pharmaceutical companies.
Riga Chem Bio is recognized as a leading company in the domestic ADC sector. Since its first technology transfer in 2015, it has signed a total of 15 technology transfer contracts worth 9.6 trillion won with global pharmaceutical companies in the U.S., U.K., China, and Japan. Its proprietary ADC platform, ConjuALL, has been awarded at the World ADC Awards for seven consecutive years, underscoring its technological prowess.
The company is also accelerating its global clinical trials. Riga Chem Bio is currently conducting eight global clinical trials, with its breast cancer treatment having entered Phase 3. Additionally, it is developing next-generation platforms, including a dual-antibody ADC and AIC·ADIC technology that combines immune stimulants.
Analysts expect the momentum for technology transfers to continue. Lee Ho-cheol, a researcher at Shinhan Investment Corp, stated, "Riga Chem Bio is the only domestic company to have transferred TROP2-targeted ADC technology to a global big pharma," adding that the entry of LCB84 into global Phase 2 trials and the possibility of Johnson & Johnson exercising its remaining options are both on the horizon.
Notably, LCB84 was transferred to J&J in a deal worth a total of $1.7 billion, including a $100 million upfront payment. Shinhan Investment Corp anticipates that if J&J exercises its remaining options during the global Phase 2 process, an additional $200 million could flow into the company.
The pipeline for future projects is also robust. Partner Ono Pharmaceutical has begun global trials for LCB97, while Riga Chem Bio aims to enter global trials for its internally developed LCB02A in the third quarter of this year. Additionally, negotiations for further technology transfers are reportedly ongoing, heightening growth expectations.
From a supply-demand perspective, a favorable environment is anticipated. Shinhan Investment Corp has pointed to the potential benefits of the KOSDAQ listing system expected to be introduced in the second half of the year. Considering the company's market capitalization, global technology transfer achievements, and visibility of results, Riga Chem Bio is seen as a strong candidate for inclusion in the first tier of KOSDAQ, with expectations for inflows from related ETFs and pension funds.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.